Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis
Open Access
- 1 March 1994
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 38 (3) , 518-522
- https://doi.org/10.1128/aac.38.3.518
Abstract
We investigated the safety and efficacy of amphotericin B colloidal dispersion (ABCD) for the treatment of invasive pulmonary aspergillosis in persistently granulocytopenic rabbits. Treatment groups included ABCD in dosages of 1, 5, and 10 mg/kg/day intravenously or conventional desoxycholate amphotericin B (DAmB) at 1 mg/kg/day intravenously. Antifungal activity was directly related to increasing dosage of ABCD as determined by the concentration of Aspergillus fumigatus organisms in lungs and the frequency of hemorrhagic pulmonary lesions. At 5 and 10 mg/kg/day, there was a significant reduction in the tissue burden of A. fumigatus as measured by percent culture-positive lobes and CFU per gram of tissue (P < or = 0.001), whereas at 1 mg/kg/day measured by percent culture-positive lobes and CFU per gram of tissue (P < or = 0.001), whereas at 1 mg/kg/day the tissue burden of A. fumigatus was not significantly different from that in untreated controls. Microbiological clearance was significantly greater at 1 mg of DAmB per kg per day than at 1 mg of ABCD per kg per day (P < or = 0.001). There was no difference in microbiological clearance of bronchoalveolar lavage fluid among the treatment groups as measured by CFU per milliliter. As determined by survival, ABCD at 5.0 mg/kg/day was more effective than DAmB at 1.0 mg/kg/day and ABCD at 10 mg/kg/day. ABCD at 10 mg/kg/day was more nephrotoxic than the lower dosages of ABCD and resulted in higher mortality. Impairment of glomerular filtration developed as a direct function increasing the ABCD dosage (r = 0.77; P < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)Keywords
This publication has 21 references indexed in Scilit:
- Systemically Administered Antifungal AgentsDrugs, 1992
- Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogsAntimicrobial Agents and Chemotherapy, 1992
- Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosisAntimicrobial Agents and Chemotherapy, 1991
- Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to ratsAntimicrobial Agents and Chemotherapy, 1991
- Amphotericin B lipid complex therapy of experimental fungal infections in miceAntimicrobial Agents and Chemotherapy, 1991
- Antifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published CasesClinical Infectious Diseases, 1990
- Amphotericin B: delivery systemsAntimicrobial Agents and Chemotherapy, 1990
- Treatment of Experimental Invasive Aspergillosis with Novel Amphotericin B/Cholesterol-Sulfate ComplexesThe Journal of Infectious Diseases, 1989
- Selective Toxicity and Enhanced Therapeutic Index of Liposomal Polyene Antibiotics in Systemic Fungal InfectionsAnnals of the New York Academy of Sciences, 1985
- Aspergillosis complicating neoplastic diseaseThe American Journal of Medicine, 1973